Chronic Wound, Myofascial Pain Syndrome
Conditions
Brief summary
To verify the efficacy and safety of HA35 in chronic pain management and to further supplement effective treatments for chronic pain, we designed a proof-of-concept clinical study. This study aims to evaluate the 15-day treatment of HA35 on patients with myofascial pain syndrome and to observe the effects for up to 3 months.
Interventions
DRUGHA35 injection
HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
Sponsors
Nakhia Impex LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male and female, aged 18-65 years old ; * suffering from muscle strain, sprain, fall, wind and other diagnosed as myofascitis in patients with chronic back pain; * the pain reported by the subject should reach level 3 or higher on the digital rating scale of 0-10 ( 0 means no pain, 10 represents the strongest pain imaginable ); * the mental state is good, and the pain level can be evaluated independently; * be able to cooperate with the treatment independently and sign a written consent.
Exclusion criteria
* Previous severe trauma with permanent musculoskeletal dysfunction; * symptomatic lumbar disc herniation with neurological deficits; * specific spinal diseases, including rheumatoid arthritis, ankylosing spondylitis, and osteoporosis; * diagnosed with mental illness; * agree not to sign the written consent; * pregnant, lactating or fertile women; * currently participating ( or participating in the past 30 days ) in research-based treatment or equipment trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chronic myofascial pain score | after treatment 1 day, 3 days, 5 days, 15 days, 30 days, 60 days, 90 days | Subjective measurements of pain were submitted using the Numerical Pain Rating Scale (NPRS). Scored at 0-10, the higher the score, the more obvious the pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall pain assessment during injection therapy and follow-up | after treatment 15 days, 30 days, 60 days, 90 days | The global pain scale (GPS) was used to assess the global pain. The total consists of 20 items, each rated on a scale from 0 to 10. The sum of the scores for all items is divided by 2 to obtain the total score. The higher the score, the more significant the pain and its impact. |
| Satisfaction survey of injection treatment | after treatment 90 days | A questionnaire survey was conducted on patients using the Satisfaction with Medication Questionnaire ( TSQM 1.4 ). There are 4 subscales and 14 questions: the Effectiveness Scale (questions 1-3), the Side Effects Scale (questions 4-8), the Convenience Scale (questions 9-11), and the Overall Satisfaction Scale (questions 12-14). Each subscale is scored from 0 to 100, with higher scores indicating greater satisfaction. |
Countries
Mongolia
Outcome results
None listed